Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.41B | 2.36B | 2.24B | 2.12B | 1.98B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.41B | 2.36B | 2.24B | 2.12B | 1.98B |
| Cost of Revenue | 870.60M | 765.10M | 716.20M | 666.60M | 623.60M |
| Gross Profit | 1.54B | 1.59B | 1.53B | 1.45B | 1.36B |
| SG&A Expenses | 1.05B | 1.02B | 938.30M | 908.20M | 888.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.93B | 1.79B | 1.65B | 1.57B | 1.51B |
| Operating Income | 487.40M | 569.00M | 588.30M | 544.70M | 470.40M |
| Income Before Tax | 466.20M | 486.00M | 521.60M | 446.90M | 469.90M |
| Income Tax Expenses | 160.40M | 144.70M | 135.70M | 107.70M | 100.20M |
| Earnings from Continuing Operations | 305.80 | 341.30 | 385.90 | 339.20 | 369.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 305.80M | 341.30M | 385.90M | 339.20M | 369.70M |
| EBIT | 487.40M | 569.00M | 588.30M | 544.70M | 470.40M |
| EBITDA | 515.90M | 596.10M | 614.00M | 569.40M | 492.90M |
| EPS Basic | 3.04 | 3.39 | 3.86 | 3.43 | 3.76 |
| Normalized Basic EPS | 3.59 | 4.10 | 4.22 | 3.93 | 3.41 |
| EPS Diluted | 2.95 | 3.29 | 3.74 | 3.32 | 3.64 |
| Normalized Diluted EPS | 3.48 | 3.98 | 4.08 | 3.79 | 3.29 |
| Average Basic Shares Outstanding | 401.60M | 401.70M | 400.10M | 396.90M | 393.70M |
| Average Diluted Shares Outstanding | 413.60M | 414.70M | 414.10M | 410.90M | 407.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |